Archive for pulmonary inflammatory disease

Syntrix Featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA

Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small Business Innovation Research (SBIR) grantees.  In addition, Syntrix was granted an additional opportunity to present their innovative research at the NIH Booth located in Hall A of the Discovery Zone.  The Syntrix presentation featured SX-682, […]

Syntrix Presents at the 2014 ACA Summit in Washington, D.C.

Syntrix was invited to present at the 2014 Angel Capital Association (ACA) Summit co-sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, angel investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured SX-682, the […]

Syntrix Receives $3.8M Grant to Develop New Treatment for COPD and Lung Disease Affecting Newborns

Congratulations to Syntrix scientists on their new grant for $3.8M from the National Hearth Lung and Blood Institute (NHBLI) of the National Institutes of Health (NIH). The project title is “Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD.” Here is the public health relevance from the proposal: “Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) […]